Palmitoylethanolamide attracts scientific attention. Since its discovery in 1957 and the clarification of one of its key mechanisms by the Nobel laureate Rita Levi-Montalcini, many researchers have devoted time to this key molecule for repair and defence.
With the publication “Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors.” by the group of Aghaei in august 2015, the line of 500 publications referred to in PubMed, is crossed.
Palmitoylethanolamide: more interest due to Levi-Montalcini and Della Valle
Palmitoylethanolamide gained much new interest after 1993, when the first work of Levi-Montalcini was published and the research group of Dr Franscesco Della Valle, a close friend to Rita, started working on the molecule. Dr Della Valle was a key person in the history of the molecule, because he and his group were the first to develop PEA, initially for the treatment of sciatic pain and multiple scleroses. Since their development work PEA became more known and clinicians started working with PEA.
The first commercial PEA products became available in the 70s of last century, as Impulsin and Palmidrol, but only after Dr Della Valle focussed more from a drug development point on the molecule the break-through in international literature became a reality.
From the start of this century a surge of interest emerged for PEA and its clinical possibilities. Increasing numbers of physicians work with the compound and are impressed by its clinical potential. Meanwhile, worldwide many more than millions of patients have been treated, and no serious dose-limiting side effects have been seen.
PEA is a breakthrough in medicine and should be used more frequently in the treatment of chronic pain and chronic inflammations.
Reference: Aghaei I, Rostampour M, Shabani M, Naderi N, Motamedi F, Babaei P, Khakpour-Taleghani B. Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors. Epilepsy Res. 2015 Aug 14;117:23-28. doi: 10.1016/j.eplepsyres.2015.08.010.